FDA approves GSK's Hibsago for chronic hepatitis B treatment

Go back to FDA approves GSK's Hibsago for chronic hepatitis B treatment
(NASDAQ: IONS) Delayed: 44.27 -1.13 (2.49%)
Previous Close $45.40    52 Week High $62.68 
Open $45.55    52 Week Low $19.59 
Day High $45.76    P/E N/A 
Day Low $44.26    EPS $0.00 
Volume 2,269,112